{"id":59642,"date":"2024-02-28T06:08:14","date_gmt":"2024-02-28T06:08:14","guid":{"rendered":"https:\/\/medsname.com\/trazalon\/"},"modified":"2026-05-01T10:49:15","modified_gmt":"2026-05-01T10:49:15","slug":"trazalon","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/trazalon\/","title":{"rendered":"Trazalon"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Rychl\u00e1 odpov\u011b\u010f \u2014 Co je Trazalon?<\/h3>\n
\n

Trazalon<\/strong> obsahuje hydrochlorid trazodonu (100 mg)<\/strong> od v\u00fdrobce certifikovan\u00e9ho WHO-GMP (Sun Pharma) \u2014 SARI<\/strong> antidepresivum, jeho\u017e hlavn\u00ed modern\u00ed vyu\u017eit\u00ed je l\u00e9\u010dba nespavosti v n\u00edzk\u00fdch d\u00e1vk\u00e1ch (25\u2013100 mg p\u0159ed span\u00edm)<\/strong> sp\u00ed\u0161e ne\u017e deprese. Mechanismus: 5-HT2A<\/sub> antagonismus plus slab\u00fd SRI plus alfa-1 antagonismus plus H1<\/sub> antagonismus \u2014 kombinace 5-HT2A<\/sub>\/H1<\/sub>\/alfa-1 zp\u016fsobuje sedaci. Antidepresivn\u00ed d\u00e1vky (150\u2013400 mg\/den)<\/strong> jsou dnes neobvykl\u00e9 \u2014 SSRI a SNRI v\u011bt\u0161inou nahradily trazodon u MDD. Off-label pou\u017eit\u00ed p\u0159i nespavosti je jeho hlavn\u00edm vyu\u017eit\u00edm. D\u016fle\u017eit\u00e1 varov\u00e1n\u00ed: priapismus<\/strong> (vz\u00e1cn\u00e9, 1 z 1 000\u201310 000 \u2014 nouzov\u00e1 situace pokud > 4 h), ortostatick\u00e1 hypotenze (alfa-1), prodlou\u017een\u00ed QT intervalu p\u0159i vysok\u00fdch d\u00e1vk\u00e1ch. Velmi bezpe\u010dn\u00e9 p\u0159i p\u0159ed\u00e1vkov\u00e1n\u00ed<\/strong> ve srovn\u00e1n\u00ed s TCA.<\/p>\n<\/div>\n

\nCo z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n

Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n

Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n<\/div>\n

D\u016fle\u017eit\u00e9 \u2014 nejedn\u00e1 se o l\u00e9k na situa\u010dn\u00ed \u00fazkost.<\/strong> Trazalon je antagonista serotoninu a inhibitor zp\u011btn\u00e9ho vychyt\u00e1v\u00e1n\u00ed (SARI)<\/strong>, p\u0159edepisov\u00e1n a titrov\u00e1n po t\u00fddny pro z\u00e1va\u017en\u00e1 depresivn\u00ed porucha (MDD); off-label \u010dasto pou\u017e\u00edv\u00e1n v n\u00edzk\u00fdch d\u00e1vk\u00e1ch p\u0159i chronick\u00e9 nespavosti<\/strong>. Nen\u00ed ne<\/strong> spr\u00e1vn\u00fdm l\u00e9kem pro akutn\u00ed, v\u00fdkonov\u011b souvisej\u00edc\u00ed \u00fazkost (l\u00e9t\u00e1n\u00ed, ve\u0159ejn\u00e9 vystupov\u00e1n\u00ed, zkou\u0161ky) \u2014 pro tyto p\u0159\u00edpady jsou klinicky vhodn\u011bj\u0161\u00ed betablok\u00e1tory (propranolol), benzodiazepiny nebo hydroxyzin. Pokud nem\u00e1te diagnostikovanou poruchu n\u00e1lady, \u00fazkostnou nebo psychiatrickou poruchu, neza\u010d\u00ednejte s u\u017e\u00edv\u00e1n\u00edm tohoto l\u00e9ku.<\/div>\n
FDA \u010dern\u00e9 varov\u00e1n\u00ed \u2014 sebevra\u017eednost.<\/strong> V\u0161echna antidepresiva nesou \u010dern\u00e9 varov\u00e1n\u00ed FDA pro zv\u00fd\u0161en\u00e9 riziko sebevra\u017eedn\u00e9ho my\u0161len\u00ed a chov\u00e1n\u00ed u d\u011bt\u00ed, dosp\u00edvaj\u00edc\u00edch a mlad\u00fdch dosp\u011bl\u00fdch do 25 let, zejm\u00e9na b\u011bhem prvn\u00edch t\u00fddn\u016f l\u00e9\u010dby nebo po zm\u011bn\u00e1ch d\u00e1vkov\u00e1n\u00ed. \u010clenov\u00e9 rodiny a p\u0159edepisuj\u00edc\u00ed l\u00e9ka\u0159i by m\u011bli pe\u010dliv\u011b sledovat zhor\u0161en\u00ed n\u00e1lady, agitovanost nebo sebevra\u017eedn\u00e9 my\u0161lenky v t\u00e9to v\u011bkov\u00e9 skupin\u011b.<\/div>\n

Co je Trazalon?<\/h2>\n

Trazalon je peror\u00e1ln\u00ed tableta hydrochlorid trazodonu (100 mg)<\/strong> vyr\u00e1b\u011bn\u00e1 spole\u010dnost\u00ed Sun Pharma. Trazodon (americk\u00e1 zna\u010dka Desyrel<\/strong>) je antagonista serotoninu a inhibitor zp\u011btn\u00e9ho vychyt\u00e1v\u00e1n\u00ed (SARI)<\/strong> byl uveden na trh v roce 1981. Blokuje 5-HT2A<\/sub> receptory siln\u011b, slab\u011b inhibuje serotoninov\u00fd transport\u00e9r a antagonizuje alfa-1 adrenergn\u00ed a H1<\/sub> histaminov\u00e9 receptory. Tato kombinace je v\u00fdrazn\u011b sedativn\u00ed \u2014 proto se trazodon v modern\u00ed praxi pou\u017e\u00edv\u00e1 sp\u00ed\u0161e jako off-label hypnotikum ne\u017e jako antidepresivum.<\/p>\n

Indikace<\/h2>\n
    \n
  • z\u00e1va\u017en\u00e1 depresivn\u00ed porucha<\/strong> \u2014 schv\u00e1leno, ale dnes neobvykl\u00e9 (SSRI\/SNRI jsou prvn\u00ed volbou)<\/li>\n
  • Nespavost (off-label, n\u00edzk\u00e1 d\u00e1vka)<\/strong> \u2014 nej\u010dast\u011bj\u0161\u00ed modern\u00ed pou\u017eit\u00ed; 25\u2013100 mg p\u0159ed span\u00edm<\/li>\n
  • Off-label dopl\u0148ky: nespavost vyvolan\u00e1 SSRI, \u00fazkost s nespavost\u00ed, agitace u demence (pou\u017e\u00edv\u00e1no s opatrnost\u00ed)<\/li>\n<\/ul>\n

    D\u00e1vkov\u00e1n\u00ed<\/h2>\n\n\n\n\n\n\n\n\n
    Indikace<\/th>\nStart<\/th>\nTypick\u00fd<\/th>\nMaxim\u00e1ln\u011b<\/th>\nPozn\u00e1mky<\/th>\n<\/tr>\n<\/thead>\n
    Nespavost (mimo indikaci)<\/td>\n25\u201350 mg p\u0159ed span\u00edm<\/td>\n50\u2013100 mg p\u0159ed span\u00edm<\/td>\n150 mg na noc<\/td>\nNej\u010dast\u011bji pou\u017e\u00edvan\u00e9 d\u00e1vkov\u00e1n\u00ed; \u00fa\u010dinn\u00e9 hypnotikum bez v\u00fdrazn\u00e9ho antidepresivn\u00edho \u00fa\u010dinku<\/td>\n<\/tr>\n
    MDD (schv\u00e1len\u00e1 indikace)<\/td>\n50\u201375 mg\/den v rozd\u011blen\u00fdch d\u00e1vk\u00e1ch<\/td>\n150\u2013400 mg\/den<\/td>\n600 mg\/den u hospitalizovan\u00fdch pacient\u016f<\/td>\nDenn\u00ed rozd\u011blen\u00e9 d\u00e1vky pro antidepresivn\u00ed \u00fa\u010dinek; sedace \u010dasto limituj\u00edc\u00ed<\/td>\n<\/tr>\n
    Nespavost u star\u0161\u00edch pacient\u016f<\/td>\n25 mg p\u0159ed span\u00edm<\/td>\n25\u201350 mg p\u0159ed span\u00edm<\/td>\n100 mg<\/td>\nOpatrnost \u2013 ortostatick\u00e1 hypotenze a p\u00e1dy<\/td>\n<\/tr>\n
    Porucha funkce jater<\/td>\nSn\u00ed\u017eit o 25\u201350 %<\/td>\n\u2014<\/td>\n\u2014<\/td>\nPomalej\u0161\u00ed titrace<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Vedlej\u0161\u00ed \u00fa\u010dinky<\/h2>\n

    Profil ne\u017e\u00e1douc\u00edch \u00fa\u010dink\u016f<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
    Frekvence<\/th>\n\u00da\u010dinek<\/th>\nPozn\u00e1mky<\/th>\n<\/tr>\n<\/thead>\n
    B\u011b\u017en\u00e9<\/td>\nSedace, ospalost<\/td>\n\u00da\u010del pou\u017eit\u00ed hypnotik off-label; problematick\u00e9 pro denn\u00ed d\u00e1vkov\u00e1n\u00ed<\/td>\n<\/tr>\n
    B\u011b\u017en\u00e9<\/td>\nOrtostatick\u00e1 hypotenze, z\u00e1vrat\u011b<\/td>\nBlok\u00e1da alfa-1 \u2014 riziko p\u00e1d\u016f u star\u0161\u00edch pacient\u016f<\/td>\n<\/tr>\n
    B\u011b\u017en\u00e9<\/td>\nSucho v \u00fastech, rozmazan\u00e9 vid\u011bn\u00ed<\/td>\nM\u00edrn\u00fd anticholinergn\u00ed \u00fa\u010dinek<\/td>\n<\/tr>\n
    B\u011b\u017en\u00e9<\/td>\nNevolnost, zvracen\u00ed<\/td>\nU\u017e\u00edvejte s j\u00eddlem<\/td>\n<\/tr>\n
    M\u00e9n\u011b \u010dast\u00e9<\/td>\nBolest hlavy, nosn\u00ed kongesce<\/td>\nBlok\u00e1da alfa-1<\/td>\n<\/tr>\n
    M\u00e9n\u011b \u010dast\u00e9<\/td>\nP\u0159\u00edr\u016fstek hmotnosti (m\u00edrn\u00fd)<\/td>\nM\u00e9n\u011b ne\u017e u mirtazapinu nebo paroxetinu<\/td>\n<\/tr>\n
    Vz\u00e1cn\u00e9<\/td>\nPriapismus (1 z 1 000\u201310 000)<\/td>\nP\u0159etrv\u00e1vaj\u00edc\u00ed erekce > 4 h je urologick\u00e1 pohotovost \u2014 mechanismus je blok\u00e1da alfa-1 interferuj\u00edc\u00ed s detumescenc\u00ed; mu\u017ei by m\u011bli b\u00fdt pou\u010deni a okam\u017eit\u011b hl\u00e1sit<\/td>\n<\/tr>\n
    Vz\u00e1cn\u00e9<\/td>\nProdlou\u017een\u00ed QT intervalu<\/td>\nD\u00e1vkov\u011b z\u00e1visl\u00e9; opatrnost s dal\u0161\u00edmi l\u00e9ky prodlu\u017euj\u00edc\u00edmi QT interval<\/td>\n<\/tr>\n
    Vz\u00e1cn\u00e9<\/td>\nSerotoninov\u00fd syndrom<\/td>\nInterakce<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Interakce s l\u00e9\u010divy<\/h2>\n

    Absolutn\u00ed kontraindikace<\/strong>: MAOI (14denn\u00ed vyplachovac\u00ed perioda).<\/p>\n

    Aditivn\u00ed sedace<\/strong>: alkohol, benzodiazepiny, opioidy, antihistaminika, sedativn\u00ed antipsychotika \u2014 hlavn\u00ed interak\u010dn\u00ed riziko u star\u0161\u00edch pacient\u016f.<\/p>\n

    Prodlou\u017een\u00ed QT intervalu<\/strong>: opatrnost s citalopramem (vysok\u00e9 d\u00e1vky), ondansetronem, methadonem, fluorochinolony.<\/p>\n

    CYP3A4 substr\u00e1t<\/strong>: hladiny stoupaj\u00ed p\u0159i u\u017e\u00edv\u00e1n\u00ed siln\u00fdch inhibitor\u016f (ketokonazol, ritonavir, klarithromycin) \u2014 sni\u017ete d\u00e1vku nebo se vyhn\u011bte.<\/p>\n

    Antihypertenziva<\/strong>: aditivn\u00ed ortostatick\u00e1 hypotenze s alfa-blok\u00e1tory, doxazosinem, prazosinem, terazosinem.<\/p>\n

    Pro\u010d Trazodon na nespavost?<\/h2>\n

    Trazodon se stal nej\u010dast\u011bji p\u0159edepisovan\u00fdm l\u00e9kem na nespavost mimo indikaci v mnoha zem\u00edch, p\u0159esto\u017ee form\u00e1ln\u00ed d\u016fkazy pro poruchy sp\u00e1nku jsou velmi slab\u00e9. D\u016fvody jsou pragmatick\u00e9:<\/p>\n